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dEpstein–Barr virus (EBV), a gamma herpesvirus per-
sisting in B cells of most adults, is the prototypic human
tumor virus. Persistent infection associates with malig-
nancies and proliferative syndromes mainly affecting
lymphoid and epithelial tissues (Rickinson and Kieff,
1996). EBV was discovered after Denis Burkitt, working in
Africa in the 1950s, proposed that an infectious agent
was involved in the etiology of a childhood tumor, now
known as Burkitt’s lymphoma (Burkitt, 1962). Herpesvi-
rus-like particles were subsequently observed on elec-
tron microscopic examination of cell lines derived from
these tumors (Epstein et al., 1964). In lymphoid tissues
BV-associated tumors include Burkitt’s lymphoma,
odgkin’s disease, and certain adult T-cell lymphomas.
BV infection associates with the epithelial disorders
asopharyngeal carcinoma, gastric carcinoma, and oral
airy leukoplakia (Osato and Imai, 1996; Rickinson and
ieff, 1996), the latter occurring in immunocompromised
atients. In this group the presence of EBV also associ-
tes with lymphoproliferative diseases and with leiomy-
sarcoma, a tumor of smooth muscle origin. EBV ge-
omes and gene expression have been detected in
reast cancers (Bonnet et al., 1999; Labrecque et al.,
995). Evidence for this association, e.g., detection of
iral genomes in each malignant cell within a tumor, has
een reviewed recently by Cohen (2000). As exhibited by
he range of pathology described above, EBV clearly
ains entry to a variety of cell types, notably B cells and
pithelial cells. Studies of EBV biology have been facili-
ated by construction of viruses containing drug resis-
ance markers, for example that described by Shimizu et
l. (1996). A recent enhancement of this approach is
evelopment of viruses carrying reporter genes, such as
hat designated EBfaV–GFP (Speck et al., 1999; Speck
nd Longnecker, 1999), which bears the gene for en-
anced green fluorescent protein (EGFP) and producese
h
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1nfectious virus in high titer. Use of this reagent enables
he ready visualization and enumeration of infected cells.
he strategies EBV has evolved to enter its various target
ells are complex and incompletely understood. How-
ver, evidence is accumulating that entry of EBV, like
any other viruses, involves interactions between sev-
ral viral glycoproteins and multiple cellular entry medi-
tors.
EBV readily infects human B cells in vitro, with initial
ttachment mediated by binding (Fig. 1) of the EBV major
uter envelope glycoprotein, gp350/220, with cellular
D21 (Nemerow et al., 1985; reviewed in Kieff, 1996).
nduction of high-level expression of CD21 on normally
ninfectable cells such as mouse L cells, human T or
rythroleukemia cells, or transformed epithelial cells
eads to viral adsorption and inefficient infection (Ahearn
t al., 1988; Koizumi et al., 1992; Li et al., 1992; Paterson
t al., 1995). From this it has been inferred that the
pecific role of CD21 in EBV infection is to capture virions
t the cell surface. The level of CD21 expression required
o bind virions is not known. However, BJAB cells, first
hown to be infectable in 1975 (Clements et al., 1975),
nd which express relatively low levels of CD21 com-
ared to other lymphoblastoid cell lines (Speck and
ongnecker, 1999), are readily infectable. As with other
erpesviruses, such as herpes simplex, additional mol-
cules are necessary and required for postbinding
vents such as fusion of virus and cell membranes and
irus internalization. Table 1 lists EBV glycoproteins in-
olved in viral entry.
Postbinding events in EBV infection involve a complex
f at least three additional EBV glycoproteins: gH, gL,
nd gp42 (Fig. 1). gH and its homologs are involved in
ntry of HSV and other herpesviruses (Forrester et al.,
992; Fuller et al., 1989; Gompels and Minson, 1986;
addad and Hutt-Fletcher, 1989; Miller and Hutt-Fletcher,
988; Peeters et al., 1992). The EBV gH homolog is
esignated gp85, product of the BXLF2 gene (Heineman
t al., 1988; Oba and Hutt-Fletcher, 1988). As with other
erpesviruses, gH associates with an accessory protein,
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2 MINIREVIEWa gL homolog designated gp25, product of the BKRF2
ORF (Yaswen et al., 1993). gp85 requires gp25 for its
orrect folding, transport, and function within the infected
ell (Forghani et al., 1994; Hutchinson et al., 1992; Kaye et
al., 1992; Liu et al., 1993; Roop et al., 1993; Spaete et al.,
993). Antibodies to gp85 inhibit fusion but not attach-
ent of EBV to B cells (Miller and Hutt-Fletcher, 1988).
irosomes made from EBV proteins bind and fuse with
D21-positive cells; however, without the gH–gL com-
lex they bind but do not fuse (Haddad and Hutt-Fletcher,
989). In EBV the gp25/gp85 complex associates with the
dditional glycoprotein gp42, product of the BZLF2 gene
Li et al., 1995). An antibody to the BZLF2 product inhibits
infection of B cells but not epithelial cells (Li et al., 1995),
implying a role for gp42 in entry of B cells only. The role
of gp42 in B cell infection is in penetration of cells rather
than attachment, as shown by the finding that EBV lack-
ing gp42 binds B cells normally but cannot penetrate
(Wang and Hutt-Fletcher, 1998). Hutt-Fletcher and col-
leagues showed that MHC molecule HLA-DR is a ligand
for gp42 and functions as EBV coreceptor in infection of
B cells, confirming an early report of HLA-DR participa-
tion in this process (Reisert et al., 1985).
FIG. 1. Epstein–Barr virus infection of B cells. Viral entry into B cells
involves the interaction of multiple viral and cellular molecules. The
initial attachment of virus to cell is mediated by viral gp350 binding
cellular CD21. Postbinding events, mediating internalization of the virus,
are known to include interaction between the viral gp25/gp/85/gp42
complex and MHC class II molecules (HLA-DR, -DP, or -DQ) on the cell
surface. In contrast, for epithelial cell infection the gH/gL complex does
not require gp42 and interacts with a ligand of unknown identity, and
gH appears to also have a role in attachment.
T
EBV Glycoproteins Partic
EBV gene HSV proteina EBV protei
BKRF2 gL gp25
BXLF2 gH gp85
BZLF2 gDb gp42
BALF4 gB gp110
BLLF1 gCb gp350/220
a The herpes simplex virus (HSV) glycoproteins which share sequen
b Although having no sequence homology with EBV glycoproteins, these H
c May serve as fusion complex for EBV B cell entry. Epithelial cell entry doOther molecules are capable of participation in EBV
entry (Fig. 1). Haan and colleagues demonstrated that
transient expression of HLA-DP or HLA-DQ on CD21-
positive, MHC class II-deleted lymphoblastoid cells ren-
ders them infectable, showing that these MHC class II
isotypes also function as EBV entry mediators (Haan et
al., 2000). While it appears that all HLA-DR and -DP
molecules function as coreceptors, only -DQ molecules
encoding a glutamic acid residue at amino acid 46 of the
mature b chain are able to mediate entry (Haan and
Longnecker, 2000). This finding is consistent with the
groove between the b1 and b2 domains of the HLA
olecule being important for gp42 binding and also
aises the possibility that EBV-related sequelae might be
elated to HLA haplotype. The possibility that B cells
ossess other EBV entry mediators is suggested by the
bservation that B cells from bare lymphocyte syndrome
atients, which in some cases appear to completely lack
xpression of HLA-DR, -DP, or -DQ, have been infected
ith and transformed by EBV. It is not known whether the
nitial binding of EBV to B cells can be mediated by
olecules other than CD21. In our hands transient ex-
ression of HLA-DR on mouse B cells does not render
hem infectable, showing that infection is not mediated
y HLA-DR alone (data not shown).
The mechanisms underlying EBV infection of epithelial
ells remain unclear, in part because an overwhelming
ajority of epithelial cell lines are refractory to EBV
nfection in vitro. Several routes for direct infection of EBV
irions into epithelial cells have been reported, without a
ommon theme emerging. Nonetheless, mechanisms of
iral entry into these cell types show a clear divergence
rom the mechanisms employed in B cell entry. Yo-
hiyama and colleagues, using EBV bearing a drug re-
istance gene, describe EBV infection of CD21-negative
astric epithelial cells as shown by derivation of drug-
esistant cell colonies (Yoshiyama et al., 1997). While this
esult implies a CD21-independent infection route, it is
ossible that very low level expression of CD21 may
uffice to permit EBV entry. Fingeroth and colleagues
sing an epithelial cell line, 293, which expresses low
evels of CD21, have shown CD21-dependent infection of
in Attachment and Entry
Known or proposed function
Complexes with gp42 and gp85c
Complexes with gp42 and gp25c
Complexes with gp25 and gp85,c binds HLA class II
Virus maturation
Initial attachment by virion binding to CD21
ology and/or functional homology with EBV glycoproteins.ABLE 1
ipating
n
ce hom
SV glycoproteins may serve as functional homologues.
es not require gp42 and may require a fusion complex lacking gp42.
e
u
3MINIREVIEWthese cells by the derivation of drug-resistant colonies,
supporting the view that low level surface CD21 expres-
sion can enable EBV infection of epithelial cells (Fin-
geroth et al., 1999). Epithelial cells stably transfected to
xpress CD21 at high levels efficiently bind EBV and
ndergo a transient infection (Li et al., 1992). Recently
Hutt-Fletcher and colleagues reported that gH-deleted
EBV binds B cells normally but is impaired in attachment
to CD21-negative epithelial cells, implying existence of a
gH ligand on epithelial cells and a role for gH in attach-
ment and entry of these cells (Molesworth et al., 2000).
gp42 is dispensable for infecting cells of the CD21-
expressing epithelial line SVKCR2, yet soluble gp42 in-
hibits this infection and B cell infection, prompting a
model of EBV virions forming two types of gH–gL com-
plex, one including gp42 and the other not, with the two
forms having mutually exclusive abilities to mediate in-
fection of B cells or epithelial cells (Wang et al., 1998). A
possible role for EBV glycoprotein gp150 in epithelial
infection is suggested by the observation that recombi-
nant EBV lacking gp150 infects B cells normally but is
enhanced in its ability to infect SVKCR2 cells (Borza and
Hutt-Fletcher, 1998).
An alternative entry route into epithelial cells has been
demonstrated by Sixbey and colleagues who have
shown that certain epithelial cells expressing the IgA
receptor can internalize EBV, if bound to polymeric IgA
(pIgA) (Sixbey and Yao, 1992). In studies using a polar-
ized epithelial cell system, the EBV–pIgA complex enters
the basolateral cell surface and is modified and secreted
from the opposite (apical) surface of the cell (Gan et al.,
1997). Some individuals who have been exposed to EBV
express IgA antibodies to EBV-associated antigens in
their serum, so in these individuals infection of epithelial
cells could potentially occur by this IgA-mediated mech-
anism. Recent work with this system shows that in po-
larized MDCK epithelial cells stably expressing CD21,
viral uptake is higher on apical than on basolateral sur-
faces, despite CD21 expression predominating basolat-
erally, implying that other cell surface molecules may
participate in the virus–cell interaction (Chodosh et al.,
2000).
Cell-to-cell contact has been described as an efficient
means of EBV entry into epithelial cells. Imai and col-
leagues working with a diverse range of epithelial cell
lines derived from gastric and colon adenocarcinoma
and hepatocellular, laryngeal, lung squamous cell, and
renal cell carcinomas, found that cocultivation of these
cells with lymphoblastoid (EBV-bearing) cells leads to
EBV infection of the epithelial cells (Imai et al., 1998).
Chang and colleagues confirmed this result using naso-
pharyngeal carcinoma cells, also finding that efficient
infection occurs independently of CD21, that cell-to-cell
contact is a requirement for the infection, and that cell-
to-cell infection could be further enhanced by inducing
expression of CD21 (Chang et al., 1999). Recently in thislaboratory we have used lymphoblastoid cell lines es-
tablished by and bearing EGFP-expressing EBV to show,
by transfer of EGFP to epithelial cells cocultivated with
EGFP-expressing cell lines, that cell-to-cell spread of
EBV occurs to breast epithelial cells (Speck and Long-
necker, 2000). This finding extends the range of cell
types infected by cell-to-cell spread and reinforces the
view that EBV may be involved in breast cancer devel-
opment, as the viral genome and gene products have
been detected in these cancers (Bonnet et al., 1999;
Labrecque et al., 1995).
There is a paucity of information regarding the mech-
anisms underlying cell-to-cell spread of virus, and the
identity of virally encoded or cellular molecules partici-
pating in the process is not known. Cell-to-cell spread of
EBV into the epithelium may be of particular clinical
relevance as the cell types infected, which include gas-
tric, nasopharyngeal, and breast epithelium, are among
those in which EBV has been implicated in tumor devel-
opment.
Recent findings reveal that, like other herpesviruses
such as herpes simplex virus (Spear et al., 2000), EBV
has evolved to utilize multiple entry receptors on the cell
surface and to enter cells by multiple mechanisms, in-
volving direct virus–cell entry and cell-to-cell spread of
virus. Much of the biology of EBV entry into susceptible
cells remains obscure. Areas likely to be focused on in
the future could include (i) identification of other EBV
entry mediators; (ii) elucidation at the molecular level,
such as by X-ray crystallography, of interactions between
viral and cellular molecules participating in the attach-
ment, fusion, and entry of EBV; and (iii) study within the
infected cells of signaling triggered by events at the cell
membrane. In addition, despite the clear implication of
EBV in certain T cell tumors, there is very little knowl-
edge regarding EBV infection of T cells. Further research
to address these issues will provide new insight into the
tropism and pathogenesis of a significant human tumor
virus.
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